Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-month Phase II Long-term Extension Study of Vamorolone in Boys with Duchenne Muscular Dystrophy
2017-003568-10Phase 2Completed
- Sponsor
- ReveraGen BioPharma
- Start
- Oct 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vamorolone in Duchenne muscular dystrophy (DMD), sponsored by ReveraGen BioPharma. Primary endpoint: Serum pharmacodynamic safety biomarkers. Started Oct 2017; status: completed.
02
Drugs
vamorolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2017-003568-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003568-10.